Skip to main content
SpringerLink
Log in

Replication-Defective Herpes Simplex Virus Mutant Strains as Genital Herpes Vaccines and Vaccine Vectors

  • Chapter
  • First Online:
Replicating Vaccines

Part of the book series: Birkhäuser Advances in Infectious Diseases ((BAID))

  • 952 Accesses

Abstract

Viral vaccines have traditionally been live, attenuated viruses, or inactivated virus/subunits. Herpes simplex virus (HSV) vaccine candidates based on inactivated viruses or subunits have not been effective thus far. In addition, attenuation of HSV to make a safe vaccine candidate has not allowed good immunogenicity to be retained. Therefore, novel vaccine strategies have been initiated, including replication-defective and single-cycle HSV strains. In this chapter, I will review the design and properties of these replication-defective virus vaccine candidates and the preclinical and clinical results that have been obtained using them.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roizman B, Knipe DM, Whitley RJ (2007) Herpes simplex virus. In: Knipe DM, Howley PM (eds) Fields Virology, 5th ed. Lippincott, Williams and Wilkins, Philadelphia, PA, pp 2501–2602

    Google Scholar 

  2. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73–83

    Article  PubMed  Google Scholar 

  3. Wald A, Link K (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185:45–52

    Article  PubMed  Google Scholar 

  4. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, Defer MC, Djagbare D, Sanon A, Andonaba JB et al (2007) Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 356:790–799

    Article  CAS  PubMed  Google Scholar 

  5. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C (2008) Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 198:1804–1808

    Article  CAS  PubMed  Google Scholar 

  6. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J et al (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371:2109–2119

    Article  CAS  PubMed  Google Scholar 

  7. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, Tanton C, Ross D, Everett D, Clayton T et al (2008) Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 358:1560–1571

    Article  CAS  PubMed  Google Scholar 

  8. Stanberry LR (1995) Herpes simplex virus vaccines as immunotherapeutic agents. Trends Microbiol 3:244–247

    Article  CAS  PubMed  Google Scholar 

  9. Whitley RJ (1993) Prospects for vaccination against herpes simplex virus. Pediatr Ann 22:726–732

    CAS  PubMed  Google Scholar 

  10. Aurelian L, Kokuba H, Smith CC (1999) Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 17:1951–1963

    Article  CAS  PubMed  Google Scholar 

  11. Wachsman M, Kulka M, Smith CC, Aurelian L (2001) A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 19:1879–1890

    Article  CAS  PubMed  Google Scholar 

  12. Casanova G, Cancela R, Alonzo L, Benuto R, Magana Mdel C, Hurley DR, Fishbein E, Lara C, Gonzalez T, Ponce R et al (2002) A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 70:235–239

    PubMed  Google Scholar 

  13. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM (2008) A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. J Virol 82:8431–8441

    Article  CAS  PubMed  Google Scholar 

  14. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr, Handsfield HH, Warren T, Marr L, Tyring S et al (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV vaccine study group. JAMA 28:331–340

    Article  Google Scholar 

  15. Straus SE, Corey L, Burke RL, Savarese B, Barnum G, Krause PR, Kost RG, Meier JL, Sekulovich R, Adair SF et al (1994) Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460–1463

    Article  CAS  PubMed  Google Scholar 

  16. Straus SE, Wald A, Kost RG et al (1997) Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 176:1129–1134

    Article  CAS  PubMed  Google Scholar 

  17. Stanberry LR, Spruance SL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P et al (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347:1652–1661

    Article  CAS  PubMed  Google Scholar 

  18. Koelle DM, Corey L (2003) Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16:96–113

    Article  CAS  PubMed  Google Scholar 

  19. Nguyen LH, Knipe DM, Finberg RW (1992) Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 66:7067–7072

    CAS  PubMed  Google Scholar 

  20. Da Costa XJ, Bourne N, Stanberry LR, Knipe DM (1997) Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital herpes. Virology 232:1–12

    Article  PubMed  Google Scholar 

  21. Godowski PJ, Knipe DM (1985) Identification of a herpes simplex virus function that represses late gene expression from parental viral genomes. J Virol 55:357–365

    CAS  PubMed  Google Scholar 

  22. Da Costa XJ, Jones CA, Knipe DM (1999) Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 96:6994–6998

    Article  PubMed  Google Scholar 

  23. Da Costa XJ, Kramer MF, Zhu J, Brockman MA, Knipe DM (2000) Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 74:7963–7971

    Article  PubMed  Google Scholar 

  24. Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, Knipe DM, Cohen JI, Straus SE (2005) Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 79:410–418

    Article  CAS  PubMed  Google Scholar 

  25. Morrison LA, Knipe DM (1994) Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection. J Virol 68:689–696

    CAS  PubMed  Google Scholar 

  26. Dudek T, Mathews LC, Knipe DM (2008) Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 372:165–175

    Article  CAS  PubMed  Google Scholar 

  27. Storer JB (1966) Longevity and gross pathology at death in 22 inbred strains of mice. J Gerontol 21:404–409

    CAS  PubMed  Google Scholar 

  28. Brockman MA, Verschoor A, Zhu J, Carroll MC, Knipe DM (2006) Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells. J Virol 80:7111–7117

    Article  CAS  PubMed  Google Scholar 

  29. Morrison LA (2008) Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells. Virology 376:205–210

    Article  CAS  PubMed  Google Scholar 

  30. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, Straus SE, Cohen JI (2008) Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26:4034–4040

    Article  CAS  PubMed  Google Scholar 

  31. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI (2009) Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 200:1088–1095

    Article  CAS  PubMed  Google Scholar 

  32. Morrison LA, Da Costa XJ, Knipe DM (1998) Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 243:178–187

    Article  CAS  PubMed  Google Scholar 

  33. Malkin JE (2004) Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 11(Suppl 1):2A–23A

    PubMed  Google Scholar 

  34. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE (2006) Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964–973

    Article  CAS  PubMed  Google Scholar 

  35. van Lint AL, Torres-Lopez E, Knipe DM (2007) Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. Virology 368:227–231

    Article  PubMed  Google Scholar 

  36. Forrester A, Farrell H, Wilkinson G, Kaye J, Davis-Poynter N, Minson T (1992) Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted. J Virol 66:341–348

    CAS  PubMed  Google Scholar 

  37. Farrell HE, McLean CS, Efstathlou S, Inglls S, Minson AC (1994) Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 68:927–932

    CAS  PubMed  Google Scholar 

  38. McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, Boursnell ME, Inglis SC (1994) Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a geneitcally disabled HSV-1. J Infect Dis 170:1100–1109

    CAS  PubMed  Google Scholar 

  39. Loudon PT, Blakeley DM, Boursnell ME, Day DA, Duncan IA, Lowden RC, McLean CS, Martin G, Miller JC, Shaw ML (2001) Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients. J Gene Med 3:458–467

    Article  CAS  PubMed  Google Scholar 

  40. de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC, Shahmanesh M, Kinghorn G, Beutner KR et al (2006) A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24:914–920

    Article  PubMed  Google Scholar 

  41. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC (1994) A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77:525–535

    Article  CAS  PubMed  Google Scholar 

  42. Read GS, Frenkel N (1983) Herpes simplex virus mutants defective in the virion-associated shutoff of host polypeptide synthesis and exhibiting abnormal synthesis of alpha (immediate early) viral polypeptides. J Virol 46:498–512

    CAS  PubMed  Google Scholar 

  43. Taddeo B, Roizman B (2006) The virion host shutoff protein (UL41) of herpes simplex virus 1 is an endoribonuclease with a substrate specificity similar to that of RNase A. J Virol 80:9341–9345

    Article  CAS  PubMed  Google Scholar 

  44. He B, Gross M, Roizman B (1997) The gamma (1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 94:843–848

    Article  CAS  PubMed  Google Scholar 

  45. Melroe G, DeLuca N, Knipe DM (2004) Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production. J Virol 78:8411–8420

    Article  CAS  PubMed  Google Scholar 

  46. Liang L, Roizman B (2008) Expression of gamma interferon-dependent genes is blocked independently by virion host shutoff RNase and by US3 protein kinase. J Virol 82:4688–4696

    Article  CAS  PubMed  Google Scholar 

  47. Reszka NJ, Zhou C, Song B, Sodroski JG, Knipe DM (2010) Simian TRIM5α proteins reduce replication of herpes simplex virus. Virology 398:243–250

    Article  CAS  PubMed  Google Scholar 

  48. Walker J, Leib DA (1998) Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function. Vaccine 16:1–5

    Article  CAS  PubMed  Google Scholar 

  49. Geiss BJ, Smith TJ, Leib DA, Morrison LA (2000) Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain. J Virol 74:11137–11144

    Article  CAS  PubMed  Google Scholar 

  50. Reszka NJ, Dudek T, Knipe DM (2010) Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 28(15):2754–62

    Article  CAS  PubMed  Google Scholar 

  51. Vagvala SP, Thebeau LG, Wilson SR, Morrison LA (2009) Virus-encoded B7-2 costimulation molecules enhance the protective capacity of a replication-defective HSV-2 vaccine in immunocompetent mice. J Virol 83:953–960

    Article  CAS  PubMed  Google Scholar 

  52. Mbizvo MT, Mashu A, Chipato T, Makura E, Bopoto R, Fottrell PF (1996) Trends in HIV-1 and HIV-2 prevalence and risk factors in pregnant women in Harare, Zimbabwe. Cent Afr J Med 42:14–21

    CAS  PubMed  Google Scholar 

  53. Greenblatt RM, Lukehart SA, Plummer FA, Quinn TC, Critchlow CW, Ashley RL, D'Costa LJ, Ndinya-Achola JO, Corey L, Ronald AR et al (1988) Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 2:47–50

    Article  CAS  PubMed  Google Scholar 

  54. Mostad SB, Kreiss JK, Ryncarz AJ, Mandaliya K, Chohan B, Ndinya-Achola J, Bwayo JJ, Corey L (2000) Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis 181:58–63

    Article  CAS  PubMed  Google Scholar 

  55. Norberg P, Kasubi MJ, Haarr L, Bergstrom T, Liljeqvist JA (2007) Divergence and recombination of clinical herpes simplex virus type 2 isolates. J Virol 81:13158–13167

    Article  CAS  PubMed  Google Scholar 

  56. Knipe DM, Ruyechan WT, Roizman B, Halliburton IW (1978) Molecular genetics of herpes simplex virus: demonstration of regions of obligatory and nonobligatory identity within diploid regions of the genome by sequence replacement and insertion. Proc Natl Acad Sci USA 75:3896–3900

    Article  CAS  PubMed  Google Scholar 

  57. Brubaker JO, Thompson CM, Morrison LA, Knipe DM, Siber GB, Finberg RW (1996) Th1-associated immune responses to beta-galactosidase expressed by replication-defective herpes simplex virus. J Immunol 157:1598–1604

    CAS  PubMed  Google Scholar 

  58. Murphy CG, Lucas WT, Means R, Czajak S, Hale CL, Lifson JD, Kauer A, Johnson RP, Knipe DM, Desrosiers RC (2000) Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 74:7745–7754

    Article  CAS  PubMed  Google Scholar 

  59. Watanabe D, Brockman MA, Ndung'u T, Mathews L, Lucas WT, Murphy CG, Felber BK, Pavlakis GN, Deluca NA, Knipe DM (2007) Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector. Virology 357:186–198

    Article  CAS  PubMed  Google Scholar 

  60. Kaur A, Sanford HB, Garry D, Lang S, Klumpp SA, Watanabe D, Bronson RT, Lifson JD, Rosati M, Pavlakis GN et al (2007) Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 357:199–214

    Article  CAS  PubMed  Google Scholar 

  61. Liu X, Broberg E, Watanabe D, Dudek T, DeLuca N, Knipe DM (2009) Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine 27:2760–2767

    Article  CAS  PubMed  Google Scholar 

  62. Spaete RR, Frenkel N (1982) The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30:295–304

    Article  CAS  PubMed  Google Scholar 

  63. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, Wild P, Geller AI (1996) Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 70:7190–7197

    CAS  PubMed  Google Scholar 

  64. Hocknell PK, Wiley RD, Wang X, Evans TG, Bowers WJ, Hanke T, Federoff HJ, Dewhurst S (2002) Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol 76:5565–5580

    Article  CAS  PubMed  Google Scholar 

  65. Duke CM, Maguire CA, Keefer MC, Federoff HJ, Bowers WJ, Dewhurst S (2007) HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime. Vaccine 25:7410–7421

    Article  CAS  PubMed  Google Scholar 

  66. Cliffe AR, Knipe DM (2008) Herpes simplex virus ICP0 promotes both histone removal and acetylation on viral DNA during lytic infection. J Virol 82:12030–12038

    Article  CAS  PubMed  Google Scholar 

  67. Suzuki M, Kasai K, Ohtsuki A, Godlewski J, Nowicki MO, Chiocca EA, Saeki Y (2009) ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression. Mol Ther 17:705–715

    Article  Google Scholar 

  68. van Lint A, Murawski MR, Goodbody RE, Severa M, Fitzgerald KA, Finberg RW, Knipe DM, Kurt-Jones EA (2010) Herpes simplex virus immediate-early ICP0 protein inhibits TLR2-dependent inflammatory responses and NF-ÎşB signaling. J Virol epublished PMID 20686034.

    Google Scholar 

Download references

Acknowledgments

Research in the author’s laboratory on HSV vaccines is supported by NIH grant AI057552 and on HSV vaccine vectors is supported by NIH grant HIVRAD grant AI46006. DMK is co-inventor on a patent on HSV replication-defective mutant vaccine technology that has been licensed by Harvard University to Sanofi Pasteur Biologicals. DMK is a consultant to Sanofi Pasteur Biologicals.

Author information

Authors and Affiliations

  1. Harvard Medical School, Department of Microbiology and Molecular Genetics, 200 Longwood Avenue, Boston, MA, 02115, USA

    David M. Knipe

Authors
  1. David M. Knipe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M. Knipe .

Editor information

Editors and Affiliations

  1. Novartis Vaccines & Diagnostics, Sydney St. 45, Cambridge, 02139, Massachusetts, USA

    Philip R. Dormitzer

  2. Novartis Vaccines & Diagnostics, Inc., Massachusetts Ave. 350, Cambridge, 02139, Massachusetts, USA

    Christian W. Mandl

  3. Novartis Vaccines & Diagnostics S.r.l., Via Fiorentina 1, Siena, 53100, Italy

    Rino Rappuoli

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Basel

About this chapter

Cite this chapter

Knipe, D.M. (2011). Replication-Defective Herpes Simplex Virus Mutant Strains as Genital Herpes Vaccines and Vaccine Vectors. In: Dormitzer, P., Mandl, C., Rappuoli, R. (eds) Replicating Vaccines. Birkhäuser Advances in Infectious Diseases. Springer, Basel. https://doi.org/10.1007/978-3-0346-0277-8_12

Download citation

Publish with us

Policies and ethics

Search

Navigation